Format

Send to

Choose Destination
Mod Pathol. 2019 Nov;32(11):1698-1707. doi: 10.1038/s41379-019-0304-y. Epub 2019 Jun 23.

Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.

Author information

1
Department of Pathology, The University of California San Francisco, San Francisco, CA, 94115, USA.
2
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
3
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
4
Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
5
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
6
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
7
Department of Pathology, McGill University, Montreal, QC, Canada.
8
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
9
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
10
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. ksircar@mdanderson.org.
11
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. ksircar@mdanderson.org.

Abstract

Hybrid oncocytic/chromophobe tumor (HOCT) of the kidney represents a poorly understood clinicopathologic entity with pathologic features that overlap between benign renal oncocytoma (RO) and malignant chromophobe renal cell carcinoma (ChRCC). Consequently, characterization of HOCT and its separation from the foregoing entities are clinically important. The aim of this study was to describe the pathologic and molecular features of HOCT and to compare them with those of RO and ChRCC. We retrospectively identified a cohort of 73 cases with renal oncocytic tumors (19 RO, 27 HOCT, and 27 ChRCC) for whom clinical follow-up data were available by 2 tertiary care hospitals. All cases were sporadic except for 2 HOCTs that were associated with Birt-Hogg-Dubé syndrome. Lesional tissues were retrieved for molecular analysis. We performed targeted gene sequencing of all exons of 261 cancer related genes on a subset of HOCT samples (n = 16). Gene expression profiling of a customized codeset was conducted on 19 RO, 24 HOCT, and 27 ChRCC samples. Clinicopathologic characteristics as well as DNA copy number alterations, mutational and transcriptional features of HOCT derived from sequencing and expression profiling data are described and compared to those in RO and ChRCC. HOCTs were more frequently multifocal and did not exhibit mutations in genes that are recurrently mutated in RO or ChRCC but showed copy number alterations primarily involving losses in chromosomes 1 and X/Y. The mRNA transcript data show that HOCT can be separated from RO and ChRCC. Hence, HOCT appears to represent a distinct renal tumor entity with genomic features that are intermediate between those of RO and ChRCC.

PMID:
31231128
DOI:
10.1038/s41379-019-0304-y

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center